Bioengineered Bugs expressing oligosaccharide receptor mimics: Toxin-binding probiotics for treatment and prevention of enteric infections

Bioengineered Bugs

Volumn 1, Issue 3, 2010, Pages 172-177

  Paton, Adrienne W ^a   Morona, Renato ^a   Paton, James C ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Cholera; Lipopolysaccharide; Oligosaccharide receptor; Shiga toxin; Toxin neutralization; Travelers' diarrhea

Indexed keywords

BACTERIAL TOXIN; OLIGOSACCHARIDE RECEPTOR; PROBIOTIC AGENT; RECEPTOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; CHOLERA; DRUG BINDING; HOST CELL; INTESTINE; INTESTINE INFECTION; NONHUMAN; PROPHYLAXIS; REVIEW; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; TRAVELLER DIARRHEA;

ANIMALS; BACTERIAL TOXINS; BIOENGINEERING; GRAM-NEGATIVE BACTERIA; HUMANS; INTESTINAL DISEASES; OLIGOSACCHARIDES; PROBIOTICS; RECEPTORS, CELL SURFACE;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 79851499445     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bbug.1.3.10665     Document Type: Review

References (49)

1. Karlsson K. Meaning and therapeutic potential of microbial recognition of host glycoconjugates. Mol Microbiol 1998; 19:1-11.
2. Paton AW, Morona R, Paton JC. Designer probiotics for prevention of enteric infections. Nat Rev Microbiol 2006; 4:193-200.
3. Zopf D, Roth S. Oligosaccharide anti-infective agents. Lancet 1996; 347:1017-21.
4. Mulvey G, Kitov PI, Marcato P, Bundle DR, Armstrong GD. Glycan mimicry as a basis for anti-infective drugs. Biochimie 2001; 83:841-7.
5. Schengrund C-L, Ringler NJ. Binding of Vibrio cholera toxin and the heat-labile enterotoxin of Escherichia coli to GM1, derivatives of GM1, and nonlipid oligosaccharide polyvalent ligands. J Biol Chem 1989; 264:13233-7.
6. Bovin NV, Tuzikov AB, Chinarev AA, Gambaryan AS. Multimeric glycotherapeutics: new paradigm. Glycoconj J 2004; 21:471-8.
7. Schengrund C-L. "Multivalent" saccharides: development of new approaches for inhibiting the effects of glycosphingolipid-binding pathogens. Biochem Pharmacol 2003; 65:699-707.
8. Fan E, Merritt EA, Verlinde CL, Hol WGJ. AB(5) toxins: structures and inhibitor design. Curr Opin Struct Biol 2000; 10:680-6.
9. Merritt EA, Zhang Z, Pickens JC, Ahn M, Hol WG, Fan E. Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E. coli heat labile enterotoxin. J Am Chem Soc 2002; 124:8818-24.
10. Kitov PI, Sadowska JM, Mulvey G, Armstrong GD, Ling H, Pannu NS, et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000; 403:669-72.
11. Paton JC, Paton AW. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998; 11:450-79.
12. Heinrichs DE, Yethon JA, Amor PA, Whitfield C. The assembly system for the outer core portion of R1- and R4-type lipopolysaccharides of Escherichia coli. J Biol Chem 1998; 273:29497-505.
13. Paton AW, Morona R, Paton JC. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 2000; 6:265-70.
14. Paton JC, Rogers TJ, Morona R, Paton AW. Oral administration of formalin-killed recombinant bacteria expressing a mimic of the Shiga toxin receptor protects mice from fatal challenge with Shiga toxigenic Escherichia coli. Infect Immun 2001; 69:1389-93.
15. Pinyon RA, Paton JC, Paton AW, Botten JA, Morona R. Refinement of a therapeutic Shiga toxin-binding probiotic for human trials. J Infect Dis 2004; 189:1547-55.
16. O157. J Clin Microbiol 1998; 36:598-602.
17. Paton JC, Paton AW. Methods for detection of STEC in humans. Methods Mol Med 2003; 73:9-26.
18. DeGrandis S, Law H, Brunton J, Gyles C, Lingwood CA. Globotetraosyl ceramide is recognized by the pig edema disease toxin. J Biol Chem 1989; 264:12520-5.
19. Paton AW, Morona R, Paton JC. Neutralization of Shiga toxins Stx1, Stx2c and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose. Infect Immun 2001; 69:1967-70.
20. Paton AW, Srimanote P, Talbot UM, Wang H, Paton JC. A new family of potent AB5 cytotoxins produced by Shiga toxigenic Escherichia coli. J Exp Med 2004; 200:35-46.
21. Paton AW, Beddoe T, Thorpe CM, Whisstock JC, Wilce MCJ, Rossjohn J, et al. AB5 subtilase cytotoxin inactivates the endoplasmic reticulum chaperone BiP. Nature 2006; 443:548-52.
22. Wolfson J, Thorpe CM, May KL, Paton JC, Jandhyala DM, Paton AW. Subtilase cytotoxin activates PERK, ATF6 and IRE1 endoplasmic reticulum stress-signaling pathways. Cell Microbiol 2008; 10:1775-86.
23. Byres E, Paton AW, Paton JC, Löfling JC, Smith DF, Wilce MCJ, et al. Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin. Nature 2008; 456:648-52.
24. Paton AW, Jennings MP, Morona R, Focareta A, Roddam LF, Paton JC. Recombinant probiotics for treatment and prevention of travellers' diarrhea. Gastroenterology 2005; 128:1219-28.
25. Wang H, Paton JC, Paton AW. Pathologic changes in mice induced by subtilase cytotoxin, a potent new Escherichia coli AB5 toxin that targets the endoplasmic reticulum. J Infect Dis 2007; 196:1093-101.
26. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998; 11:142-201.
27. Vaandrager AB. Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C. Mol Cell Biochem 2002; 230:73-83.
28. Newburg DS. Neonatal protection by an innate immune system of human milk consisting of oligosaccharides and glycans. J Anim Sci 2009; 87:26-34.
29. Nandi A, Mathew R, Visweswariah SS. Expression of the extracellular domain of the human heat-stable enterotoxin receptor in Escherichia coli and generation of neutralizing antibodies. Prot Ex. Pu 1996; 15:271-81.
30. Angstrom J, Teneberg S, Karlsson KA. Delineation and comparison of ganglioside-binding epitopes for the toxins of Vibrio cholerae, Escherichia coli and Clostridium tetani: evidence for overlapping epitopes. Proc Natl Acad Sci USA 1994; 91:11859-63.
31. Angstrom J, Bäckström M, Berntsson A, Karlsson N, Holmgren J, Karlsson KA, et al. Novel carbohydrate binding site recognizing blood group A and B determinants in a hybrid of cholera toxin and Escherichia coli heat-labile enterotoxin B-subunits. J Biol Chem 2000; 275:3231-8.
32. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet 2004; 363:223-33.
33. Focareta A, Paton JC, Morona R, Cook J, Paton AW. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 2006; 130:1688-95.
34. Hughes R. Campylobacter jejuni in Guillain-Barré syndrome. Lancet Neurol 2004; 3:644.
35. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002; 125:2591-625.
36. Prendergast MM, Moran AP. Lipopolysaccharides in the development of the Guillain-Barré syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. J Endotoxin Res 2000; 6:341-59.
37. Nachamkin I, Liu J, Li M, Ung H, Moran AP, Prendergast MM, Sheikh K. Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GD(1a)-like epitope. Infect Immun 2002; 70:5299-303.
38. Godschalk PC, Kuijf ML, Li J, St. Michael F, Ang CW, Jacobs BC, et al. Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes. Infect Immun 2007; 75:1245-54.
39. Gilbert M, Karwaski MF, Bernatchez S, Young NM, Taboada E, Michniewicz J, et al. The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem 2002; 277:327-37.
40. Linton D, Gilbert M, Hitchen PG, Dell A, Morris HR, Wakarchuk WW, et al. Phase variation of a β-1,3 galactosyltransferase involved in generation of the ganglioside GM1-like lipo-oligosaccharide of Campylobacter jejuni. Mol Microbiol 2000; 37:501-14.
41. Guerry P, Szymanski CM. Camplylobacter sugars sticking out. Trends Microbiol 2008; 16:428-35.
42. Yuki N, Susuki K, Koga M, Nishimoto Y, Odaka M, Hirata K, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci USA 2004; 101:11404-9.
43. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005; 18:247-63.
44. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176-9.
45. Na X, Kim H, Moyer MP, Pothoulakis C, LaMont JT. gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A. Infect Immun 2008; 76:2862-71.
46. Tucker KD, Wilkins TD. Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X and Y. Infect Immun 1991; 59:73-8.
47. Dingle T, Wee S, Mulvey GL, Greco A, Kitova EN, Sun J, et al. Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile. Glycobiology 2008; 18:698-706.
48. Bode L, Rudloff S, Kunz C, Strobel S, Klein N. Human milk oligosaccharides reduce platelet-neutrophil complex formation leading to a decrease in neutrophil beta2 integrin expression. J Leukoc Biol 2004; 76:820-6.
49. Moran AP, Prendergast MM, Appelmelk BJ. Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. FEMS Immunol Med Microbiol 1996; 16:105-15.